This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief [CNBC]
Ionis Pharmaceuticals (NASDAQ:IONS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $95.00 price target on the stock.
Ionis Pharmaceuticals (NASDAQ:IONS) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
Assessing Ionis Pharmaceuticals (IONS) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]